2-(2'-Hydroxy-3',5'-di-tert-butylphenyl)benzotriazole

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:17934922	IVR	2.5 mg/kg/day	2.5 mg/kg/day	Liver hypertrophy	Hepatic endocrine-mediated perturbations
	IVR	2.5 mg/kg/day	2.5 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	2.5 mg/kg/day	2.5 mg/kg/day	Changes in haemocrit values	Immunological endocrine-mediated perturbations
	IVR	2.5 mg/kg/day	2.5 mg/kg/day	Changes in morphology of thyroid gland	Metabolic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Changes in morphology of thyroid gland	Metabolic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Increased Aspartate aminotransferase (AST) levels	Hepatic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Changes in haemocrit values	Immunological endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Liver hypertrophy	Hepatic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Increased Alanine aminotransferase (ALT) levels	Hepatic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Elevated glucose levels	Metabolic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Affects the biochemical composition of liver	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Liver hypertrophy	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased Alkaline phosphatase (ALP) levels	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased Alanine aminotransferase (ALT) levels	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased Aspartate aminotransferase (AST) level	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased triglycerides level	Metabolic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Changes in morphology of thyroid gland	Metabolic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased cholesterol levels	Metabolic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Changes in haemocrit values	Immunological endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Elevated glucose levels	Metabolic endocrine-mediated perturbations
	IVR	0.5 mg/kg/day	0.5 mg/kg/day	Liver hypertrophy	Hepatic endocrine-mediated perturbations
	IVR	2.5 mg/kg/day	2.5 mg/kg/day	Elevated glucose levels	Metabolic endocrine-mediated perturbations
PMID:18161511	IVR	2.5 mg/kg/day	2.5 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	2.5 mg/kg/day	2.5 mg/kg/day	Liver hypertrophy	Hepatic endocrine-mediated perturbations
	IVR	2.5 mg/kg/day	2.5 mg/kg/day	Increased Lactate dehydrogenase (LDH) levels	Metabolic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Increased Alanine aminotransferase (ALT) levels	Hepatic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Increased Lactate dehydrogenase (LDH) levels	Metabolic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Liver hypertrophy	Hepatic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Increased Aspartate aminotransferase (AST) level	Hepatic endocrine-mediated perturbations
	IVR	12.5 mg/kg/day	12.5 mg/kg/day	Increased Alkaline phosphatase (ALP) levels	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Liver hypertrophy	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased Lactate dehydrogenase (LDH) levels	Metabolic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased Aspartate aminotransferase (AST) level	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased Alkaline phosphatase (ALP) levels	Hepatic endocrine-mediated perturbations
	IVR	62.5 mg/kg/day	62.5 mg/kg/day	Increased Alanine aminotransferase (ALT) levels	Hepatic endocrine-mediated perturbations
	IVR	0.5 mg/kg/day	0.5 mg/kg/day	Increased Lactate dehydrogenase (LDH) levels	Metabolic endocrine-mediated perturbations
	IVR	0.5 mg/kg/day	0.5 mg/kg/day	Liver hypertrophy	Hepatic endocrine-mediated perturbations
	IVR	0.5 mg/kg/day	0.5 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
PMID:27665778	IVR	2.5 mg/kg	2.5 mg/kg	Affects liver function	Hepatic endocrine-mediated perturbations
	IVR	0.5 mg/kg	0.5 mg/kg	Affects liver function	Hepatic endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.